Specifying GMP Manufacturing, Packaging, and Quality Control Testing of an Oral Capsule Drug Product for a Selective Kinase Inhibitor: A Request-for-Proposal Framework for Contract Manufacturing Organization Selection
Targeted oral oncology products are made in the same way as any other solid dosage form, yet a lapse in blend uniformity, fill weight, or labelling is magnified because the patient population is small and closely monitored. This article builds a request for proposal (RFP) for a contract manufacturing organization (CMO) to manufacture, package, and test two strengths of an immediate-release capsule for a hypothetical selective, covalent kinase inhibitor used in a molecularly defined cancer, using sponsor-supplied drug substance and a sponsor-approved formulation. It sets out the class-level rationale, a bid-ready specification for material verification, blending, capsule filling, in-process control, release testing, and labelling, a 16 to 18 week schedule, an itemized budget range of USD 450,000 to 750,000, a weighted evaluation model, and the regulatory and quality-system expectations under 21 C.F.R. Parts 210 and 211 and ICH Q8(R2), Q9(R1), and Q10. Recommendations address confidentiality, change control, and ownership of manufacturing know-how.Keywords: request for proposal; contract manufacturing organization; oral solid dosage; capsule; GMP; ICH Q10; process validation
Authors
- Peivand Pirouzi
- Riddhi Rohan Moradiya
- Aditi Shivakumar Hipparagi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425372
- Primary Topic
- Analytical Methods in Pharmaceuticals
- Type
- article
- Field-Weighted Citation Impact
- 0.00